Protocol Ledger

NCT04316117 · Phase II · ACTIVE NOT RECRUITING

Using FDG-PET/CT to Assess Response of Bone-Dominant Metastatic Breast Cancer, FEATURE Study

Interventional Phase II clinical trial protocol NCT04316117 sponsored by ECOG-ACRIN Cancer Research Group in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2020-09-15 Enrollment: 138 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04316117
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)138 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04316117
Protocol FieldVerified Registry Value
NCT IdentifierNCT04316117
Consolidated Lead SponsorECOG-ACRIN Cancer Research Group
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment138 participants (ACTUAL)
Registered Start Date2020-09-15
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI